Gordon, K., Warren, R., Gottlieb, A., Blauvelt, A., Thaci, D., Leonardi, C., Poulin, Y., Boehnlein, M., Kavanagh, S., Arendt, C. and Reich, K. (2019) “Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”, SKIN The Journal of Cutaneous Medicine, 3, p. S36. doi: 10.25251/skin.3.supp.36.